Bruker acquires Noscendo’s DISQVER metagenomic sequencing platform - BRKR News | RalliesBruker acquires Noscendo’s DISQVER metagenomic sequencing platform
B
BRKR• Bruker expands infection detection portfolio with DISQVER acquisition
- Bruker acquired the DISQVER clinical metagenomics platform from Noscendo, expanding its NGS-based infection detection portfolio.
- DISQVER analyzes WGS data from cell-free blood samples to identify pathogens without prior cultivation, with results in under 24 hours.
- The software applies proprietary bioinformatics to screen for more than 11,000 microbes and parasites, targeting severe infections such as sepsis.
- DISQVER will remain research-use-only while Bruker pursues diagnostic registration.
- Financial terms were not disclosed; the deal is not expected to be material to Bruker’s FY26 results.
